Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-Human Dose Escalation Study of HC002 to Evaluate Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

NCT06670274 is registered in ClinicalTrials.gov with Holoclara Aus Pty Ltd as lead sponsor.

NCT NCT06670274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06670274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-Human Dose Escalation Study of HC002 to Evaluate Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
Lead sponsor
Holoclara Aus Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
November 21, 2024
Completion date
May 7, 2025
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, inflammatory disease